Scotty Roberts
Analyst · Richard Close from Canaccord Genuity
Thank you, Bobby. I'll jump into the financials, beginning with a recap of our key financial metrics for the quarter. Revenues were $65.6 million, which were up 1%. Operating income was $3 million, down 14%. Net income was $3.1 million, up 26%. Earnings per share was $0.10 per share, which is up 25%. And adjusted EBITDA was $13.1 million and down 10%. Workforce Solutions revenues were $52.5 million and were up 1% and revenues from Provider Solutions were $13.2 million and were up 4%. We continue to see positive product adoption and sales momentum in areas such as our market leading learning application, the HealthStream Learning Center, clinical competency solutions like Jane, the Credential Stream application, the ShiftWizard scheduling application, and new contributions from the Rievent and CloudCME acquisitions. We are pleased with the growth of these solutions, although the year-over-year comparison, particularly in the workforce segment was impacted by two products that experienced lower revenues this quarter. The first was the expected revenue runoff from the legacy resuscitation products of approximately $0.9 million and the second was a decline in the legacy ANSOS scheduling product of $1 million. ANSOS along with NurseGrid and ShiftWizard was acquired in 2020, and collectively, they comprise our scheduling and capacity management application suite. Unlike the other two products we acquired, ANSOS features an installed software application sold under nonrecurring perpetual software licenses. During the quarter, ANSOS experienced lower new sales and a higher rate of churn of its legacy installed software. Our focus is now on upgrading legacy ANSOS customers to our recurring revenue SaaS scheduling applications, including ShiftWizard, which by the way, demonstrated 28% revenue growth compared to the same period last year. Our gross margin was 66.1% compared to 65.1% last year. As Bobby mentioned just a minute ago, our shift in product mix to higher margin solutions continues to improve our gross margin. Looking at operating expenses. Excluding cost of revenues, [sales] were up 4% or $1.7 million. As our business has grown over the past year, staffing levels, in particular, have increased and were the primary driver for expense growth over last year. Investing in sales, marketing and product development have been our primary focus to drive sales and revenue growth, and create new products and enhancements for our customers. Sales and marketing expenses increased by 15% and included a combination of increased staffing levels, sales commissions, travel and marketing spend. It's good to see the pickup in sales activity even though it brings some increased levels of expense. Product development increased by 2%, which is net of labor costs that were capitalized for software development. Capitalized labor costs increased approximately $800,000 over the prior year quarter. This increase was mainly associated with investments in the scheduling and capacity management application fleet as well as the development of courseware to create more higher margin products. As anticipated, our business travel began to pick up during the second quarter. We spent about $400,000 this quarter compared to less than $60,000 in the second quarter of last year. While $400,000 in the quarter is well below our pre-COVID travel spend, this amount exceeded what we spent for the full year of 2021. We expect that travel will continue to increase during the second half of the year, although it will likely remain below the pre-COVID levels. General and administrative expenses declined by 2%. The reduction in office lease costs and transition service costs associated with the ANSOS staff scheduling acquisition, both generated cost savings versus last year. Partially offsetting lease savings, though, were higher bad debt, software expenses, insurance premiums and costs associated with employee recruiting and onboarding. Our adjusted EBITDA was $13.1 million, which was down 10% from the record high that was set in last year's second quarter. We ended the quarter with cash and investment balances of $39.2 million, which is down by $6.2 million since last quarter. During the quarter, we deployed $3.1 million of cash for share repurchases, $6.1 million for capital expenditures and $4 million to acquire CloudCME. DSO was 45 days compared to 43 days last year. On a year-to-date basis, our cash flows from operations were $28 million compared to $24.3 million last year and free cash flows were $15 million compared to $11.6 million last year. For our share repurchase program, as I said, we spent $3.1 million under the program this quarter and we have approximately $1.9 million remaining under the program. Over this past two and half years, we've deployed over $48 million of capital towards share buybacks, retiring approximately 6.5% of our outstanding common stock in the process. The average price at which we repurchased shares over the last two and half years was $21.75 per share. We've also had a long history of deploying capital towards mergers and acquisitions. And on May 18th, we completed the acquisition of the remaining ownership interest we had in CloudCME for approximately $4 million in cash and $4.1 million in shares of our common stock. We also recognized a $0.9 million gain associated with the change in the fair value of our previously held minority interest in CloudCME. The acquisition of CloudCME complements the Rievent acquisition that we completed in December of last year. Both companies provide software solutions for CME management to accredited healthcare organizations. Now let's discuss guidance. We are reaffirming our previously issued guidance, which is as follows. Consolidated revenues are forecasted to range between $267.5 million and $273 million. Adjusted EBITDA is forecasted to range between $50 million and $53.5 million and capital expenditures are forecasted to range between $26 million and $29 million. With the first half of the year behind us and some of the year-over-year declines on the top line mostly flushed out during the first and second quarters, we expect revenues will begin showing improvement during the second half of the year. That said, as I mentioned earlier, there will be a reduced focus on selling ANSOS nonrecurring perpetual software, which will result in some drag on the top line growth. As a reminder, even the low end of our range would still result in an approximate 6% revenue growth rate for the second half of the year, which is more than double our top line growth rate for the first half of the year. From a hiring and retention perspective, through the first half of the year, our headcount increased by 4.5% through filling new positions and the addition of CloudCME employees. Our plan remains to increase staffing levels by 5% to 7% during the year. We've been able to recruit and hire effectively while our employee turnover rates remain similar to what we've experienced the past several quarters. Looking to adjusted EBITDA guidance, we expect the second half of the year will be lower than the first half, attributed in part to the expected lower sales of ANSOS nonrecurring perpetual software, and as expenses such as travel, trade shows and compensation expenses will be higher than they were in the first half of the year. Thanks for your time this morning. Bobby, I'll turn the call back over to you now.